<DOC>
	<DOCNO>NCT02657889</DOCNO>
	<brief_summary>This Phase 1/2 study evaluate safety efficacy combination treatment niraparib pembrolizumab ( MK-3475 ) patient advanced metastatic triple-negative breast cancer recurrent ovarian cancer . ( KEYNOTE-162 )</brief_summary>
	<brief_title>Study Niraparib Combination With Pembrolizumab ( MK-3475 ) Patients With Triple-negative Breast Cancer Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Niraparib</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Main Histologically proven advance ( unresectable ) metastatic cancer outline 1 . Patients triplenegative breast cancer ( TNBC ) treat least 1 prior regimen advanced/metastatic disease relapsed/progressed within 1 month completion adjuvant chemotherapy Phase 1 : Up 3 line prior chemotherapy allow Phase 2 : Up 2 line prior chemotherapy allow 2 . Patients highgrade serous ovarian , fallopian tube , primary peritoneal cancer recurrent disease previously treat chemotherapy advanced/metastatic disease experience response last least 6 month firstline platinumbased therapy currently consider platinumresistant Phase 1 : Up 4 line prior chemotherapy allow Phase 2 : Up 3 line prior chemotherapy allow Archival tumor tissue available fresh biopsy must obtain prior study treatment initiation Measurable lesion RECIST v1.1 Eastern Cooperative Oncology Group ( ECOG ) 0 1 Adequate organ function Able take oral medication Female patient , childbearing potential , negative serum pregnancy test within 72 hour take study medication agree abstain activity could result pregnancy enrollment 120 day last dose study treatment Male patient agree use adequate method contraception Main Progressed platinum treatment within 1 month completion platinumcontaining regimen line therapy Known active central nervous system ( CNS ) metastases and/or carcinomatous meningitis Note : Patients previously treat brain metastasis may able participate provide stable Patient know additional malignancy progress require active treatment within last 5 year ( exception include basal cell carcinoma skin , squamous cell carcinoma skin undergone potentially curative therapy , situ cervical cancer ) Poor medical risk Pregnant breastfeeding , expect conceive child within project duration study Immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose study treatment Known history human immunodeficiency virus ( HIV ) ( HIV 1/2 antibody ) Known active hepatitis B hepatitis C Active autoimmune disease require systemic treatment past 2 year ( ie , use diseasemodifying agent , corticosteroid , immunosuppressive drug ) . Replacement therapy ( eg , thyroxine , insulin , physiologic corticosteroid replacement therapy adrenal pituitary insufficiency , etc . ) consider form systemic treatment History interstitial lung disease Known history platelet transfusion chemotherapyinduced thrombocytopenia persistent ( &gt; 4 week ) â‰¥ Grade 3 hematological toxicity fatigue prior cancer therapy Prior treatment antiPD1 , antiPDL1 , antiPDL2 Prior treatment know poly ( ADPribose ) polymerase ( PARP ) inhibitor Heartrate correct QT interval ( QTc ) prolongation &gt; 470 msec screen Known history myelodysplastic syndrome ( MDS ) pretreatment cytogenetic test result risk diagnosis MDS/acute myeloid leukemia ( AML ) Receiving concomitant medication prolong QTc unable discontinue use</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>PARP inhibitor</keyword>
	<keyword>PD-1</keyword>
	<keyword>Niraparib</keyword>
	<keyword>Pembrolizumab</keyword>
	<keyword>Keynote</keyword>
	<keyword>TOPACIO</keyword>
</DOC>